These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 8392313

  • 21. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
    Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak M, Gu Z, Song Q, Manne J, Islam S, Castriota G, Prasad VR.
    Science; 1996 Mar 01; 271(5253):1282-5. PubMed ID: 8638110
    [Abstract] [Full Text] [Related]

  • 22. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.
    Kavlick MF, Shirasaka T, Kojima E, Pluda JM, Hui F, Yarchoan R, Mitsuya H.
    Antiviral Res; 1995 Oct 01; 28(2):133-46. PubMed ID: 8585767
    [Abstract] [Full Text] [Related]

  • 23. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1.
    Salomon H, Belmonte A, Nguyen K, Gu Z, Gelfand M, Wainberg MA.
    J Clin Microbiol; 1994 Aug 01; 32(8):2000-2. PubMed ID: 7527427
    [Abstract] [Full Text] [Related]

  • 24. Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA.
    Arts EJ, Marois JP, Gu Z, Le Grice SF, Wainberg MA.
    J Virol; 1996 Feb 01; 70(2):712-20. PubMed ID: 8551607
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs.
    Faraj A, Agrofoglio LA, Wakefield JK, McPherson S, Morrow CD, Gosselin G, Mathe C, Imbach JL, Schinazi RF, Sommadossi JP.
    Antimicrob Agents Chemother; 1994 Oct 01; 38(10):2300-5. PubMed ID: 7530932
    [Abstract] [Full Text] [Related]

  • 26. Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro.
    Gosselin G, Schinazi RF, Sommadossi JP, Mathé C, Bergogne MC, Aubertin AM, Kirn A, Imbach JL.
    Antimicrob Agents Chemother; 1994 Jun 01; 38(6):1292-7. PubMed ID: 8092827
    [Abstract] [Full Text] [Related]

  • 27. Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC.
    Gu Z, Gao Q, Faust EA, Wainberg MA.
    J Gen Virol; 1995 Oct 01; 76 ( Pt 10)():2601-5. PubMed ID: 7595365
    [Abstract] [Full Text] [Related]

  • 28. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
    Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, van Gennip AH, Berkhout B.
    EMBO J; 1996 Aug 01; 15(15):4040-9. PubMed ID: 8670908
    [Abstract] [Full Text] [Related]

  • 29. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.
    Mathez D, Schinazi RF, Liotta DC, Leibowitch J.
    Antimicrob Agents Chemother; 1993 Oct 01; 37(10):2206-11. PubMed ID: 7504908
    [Abstract] [Full Text] [Related]

  • 30. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.
    Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, Hirst HM, Cammack N, Cameron J.
    AIDS; 1995 Apr 01; 9(4):351-7. PubMed ID: 7540846
    [Abstract] [Full Text] [Related]

  • 31. Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells.
    Xie H, Voronkov M, Liotta DC, Korba BA, Schinazi RF, Richman DD, Hostetler KY.
    Antiviral Res; 1995 Oct 01; 28(2):113-20. PubMed ID: 8585765
    [Abstract] [Full Text] [Related]

  • 32. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF.
    Antivir Chem Chemother; 2000 Jul 01; 11(4):291-301. PubMed ID: 10950391
    [Abstract] [Full Text] [Related]

  • 33. Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase.
    Zhang D, Caliendo AM, Eron JJ, DeVore KM, Kaplan JC, Hirsch MS, D'Aquila RT.
    Antimicrob Agents Chemother; 1994 Feb 01; 38(2):282-7. PubMed ID: 7514856
    [Abstract] [Full Text] [Related]

  • 34. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
    Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM, Pennington KN, St Clair MH.
    J Virol; 1996 Sep 01; 70(9):5922-9. PubMed ID: 8709213
    [Abstract] [Full Text] [Related]

  • 35. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S, La Seta Catamancio S, Sheridan F, Parker D.
    J Clin Virol; 2000 Dec 01; 19(3):135-42. PubMed ID: 11090748
    [Abstract] [Full Text] [Related]

  • 36. Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.
    Balzarini J, Wedgwood O, Kruining J, Pelemans H, Heijtink R, De Clercq E, McGuigan C.
    Biochem Biophys Res Commun; 1996 Aug 14; 225(2):363-9. PubMed ID: 8753770
    [Abstract] [Full Text] [Related]

  • 37. The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro.
    Coates JA, Cammack N, Jenkinson HJ, Mutton IM, Pearson BA, Storer R, Cameron JM, Penn CR.
    Antimicrob Agents Chemother; 1992 Jan 14; 36(1):202-5. PubMed ID: 1590690
    [Abstract] [Full Text] [Related]

  • 38. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
    Shirasaka T, Yarchoan R, O'Brien MC, Husson RN, Anderson BD, Kojima E, Shimada T, Broder S, Mitsuya H.
    Proc Natl Acad Sci U S A; 1993 Jan 15; 90(2):562-6. PubMed ID: 8380641
    [Abstract] [Full Text] [Related]

  • 39. Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
    Reinis M, Vandasová J, Stanková M, Linka M, Brůcková M.
    Acta Virol; 2001 Jan 15; 45(5-6):279-86. PubMed ID: 12083326
    [Abstract] [Full Text] [Related]

  • 40. Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.
    Gobert JM, Remington KM, Zhu YQ, North TW.
    Antimicrob Agents Chemother; 1994 Apr 15; 38(4):861-4. PubMed ID: 8031060
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.